Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,081 to 1,100 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of molecular subtypes of coronary artery disease based on ferroptosis- and necroptosis-related genes. | Front Genet | 2022 | 36204316 | PubTator, text mining | PubMed |
| Methods for assessing the impact of PM2.5 concentration on mortality while controlling for socio-economic factors. | Heliyon | 2022 | 36203891 | PubTator, text mining | PubMed |
| CD8+ T cell-associated genes MS4A1 and TNFRSF17 are prognostic markers and inhibit the progression of colon cancer. | Front Oncol | 2022 | 36203424 | PubTator, text mining | PubMed |
| [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives]. | Rinsho Ketsueki | 2022 | 36198540 | PubTator, text mining | PubMed |
| B cells defined by immunoglobulin isotypes. | Clin Exp Immunol | 2022 | 36197112 | PubTator, text mining | PubMed |
| Ocular adnexal lymphoma: Subtype-specific clinical and genetic features. | Acta Ophthalmol | 2022 | 36196757 | PubTator, text mining | PubMed |
| Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12. | Exp Hematol | 2022 | 36191884 | PubTator, text mining | PubMed |
| IL-4 receptor blockade is a global repressor of naïve B cell development and responses in a dupilumab-treated patient. | Clin Immunol | 2022 | 36189576 | PubTator, text mining | PubMed |
| Loss of early B cell protein λ5 decreases bone mass and accelerates skeletal aging. | Front Immunol | 2022 | 36189270 | PubTator, text mining | PubMed |
A combined analysis of bulk and single-cell sequencing data reveals that depleted extracellular matrix and enhanced immune processes co-contribute to fluorouracil beneficial responses in gastric cancer. | Front Immunol | 2022 | 36189263 | PubTator, text mining | PubMed |
| Integrated analysis of bulk and single-cell RNA sequencing reveals the interaction of PKP1 and tumor-infiltrating B cells and their therapeutic potential for nasopharyngeal carcinoma. | Front Genet | 2022 | 36186467 | PubTator, text mining | PubMed |
| Super-Enhancer-Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients. | Front Genet | 2022 | 36186463 | PubTator, text mining | PubMed |
| BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma. | J Biol Chem | 2022 | 36183831 | PubTator, text mining | PubMed |
| BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. | J Hematol Oncol | 2022 | 36183125 | PubTator, text mining | PubMed |
| The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review. | Clin Lymphoma Myeloma Leuk | 2022 | 36182550 | PubTator, text mining | PubMed |
| Interleukin-10-1082A>G (rs1800896) Single Nucleotide Polymorphism is Not a Risk Factor of Chronic Lymphocytic Leukemia in Sudanese Population. | Asian Pac J Cancer Prev | 2022 | 36172689 | PubTator, text mining | PubMed |
| Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies. | Front Oncol | 2022 | 36172151 | PubTator, text mining | PubMed |
| Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. | J Immunother Cancer | 2022 | 36171009 | PubTator, text mining | PubMed |
| TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. | Mol Cancer | 2022 | 36163179 | PubTator, text mining | PubMed |
| Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers. | Clin Cancer Res | 2022 | 36161312 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=55